Literature DB >> 11095344

Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C.

E Giannini1, P Ceppa, F Botta, L Mastracci, P Romagnoli, I Comino, A Pasini, D Risso, P B Lantieri, G Icardi, T Barreca, R Testa.   

Abstract

OBJECTIVE: The presence of steatosis is a common histological finding in patients with chronic hepatitis C (CHC). The causes of the severity of this condition are not yet clear, although both metabolic and viral factors supposedly are involved. In this study our aim was to examine the possible influence that leptin levels, hepatitis C virus (HCV) RNA levels, and hepatitis G virus (HGV) infection have on the severity of steatosis and on the presence and degree of fibrosis in patients with CHC.
METHODS: One hundred eighty-two CHC patients with histological findings of steatosis were chosen from among a cohort of patients referred to our center for staging of liver disease. Among them 48 CHC patients were accurately selected so as to rule out possible confounding factors for the presence of steatosis (diabetes mellitus, hyperlipemia, obesity, alcohol). Leptin levels, HCV RNA levels, and HCV genotype, and the presence of HGV RNA were assessed in these patients and related to histological findings.
RESULTS: We found that leptin levels in CHC patients were similar to those in healthy subjects. No relationship was found between leptin levels and severity of steatosis. HCV RNA levels, HCV genotype, and the presence of HGV infection were no different among CHC patients with various degrees of steatosis. Leptin was not related to different degrees of fibrosis, whereas higher viral load was the only parameter associated to higher fibrosis scores.
CONCLUSIONS: These findings suggest that the degree of steatosis in patients with CHC does not seem to depend on serum leptin levels or on viral factors, at least as far as HCV viremia and genotype and HGV infection are concerned. The severity of fibrosis does not seem to be influenced by leptin levels, whereas HCV viral load does seem to play some role.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095344     DOI: 10.1111/j.1572-0241.2000.03294.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

Review 1.  Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.

Authors:  Michał Kukla; Włodzimierz Mazur; Rafał J Bułdak; Krystyna Zwirska-Korczala
Journal:  Mol Med       Date:  2011-07-05       Impact factor: 6.354

2.  Adipokines, cytokines and body fat stores in hepatitis C virus liver steatosis.

Authors:  Emilio González-Reimers; Javier López-Prieto; Geraldine Quintero-Platt; Ricardo Pelazas-González; M Remedios Alemán-Valls; Onán Pérez-Hernández; M José de-la-Vega-Prieto; M Angeles Gómez-Rodríguez; Candelaria Martín-González; Francisco Santolaria-Fernández
Journal:  World J Hepatol       Date:  2016-01-08

Review 3.  Liver steatosis in hepatitis C patients.

Authors:  Emilio González-Reimers; Geraldine Quintero-Platt; Melchor Rodríguez-Gaspar; Remedios Alemán-Valls; Onán Pérez-Hernández; Francisco Santolaria-Fernández
Journal:  World J Hepatol       Date:  2015-06-08

4.  Changes in lipid metabolism in chronic hepatitis C.

Authors:  Katalin Jármay; Gizella Karácsony; András Nagy; Zsuzsa Schaff
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

5.  Apolipoprotein-AII concentrations are associated with liver steatosis in patients with chronic hepatitis C.

Authors:  Jean Michel Petit; Valerie Jooste; Laurence Duvillard; Anne Minello; Véronique Texier; Françoise Galland; Philippe Gambert; Bruno Verges; Patrick Hillon
Journal:  Dig Dis Sci       Date:  2007-04-11       Impact factor: 3.199

Review 6.  A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

Authors:  P Riley; J O'Donohue; M Crook
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

7.  Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.

Authors:  G Esmat; Wafaa El Akel; M Metwally; A Soliman; W Doss; M Abdel Hamid; M Kamal; K Zalata; H Khattab; M El-Kassas; M Esmat; A Hasan; M El-Raziky
Journal:  Indian J Gastroenterol       Date:  2009-08-21

8.  High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C.

Authors:  Yuichiro Eguchi; Toshihiko Mizuta; Tsutomu Yasutake; Akitaka Hisatomi; Ryuichi Iwakiri; Iwata Ozaki; Kazuma Fujimoto
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

9.  Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.

Authors:  G Svegliati-Baroni; E Bugianesi; T Bouserhal; F Marini; F Ridolfi; F Tarsetti; F Ancarani; E Petrelli; E Peruzzi; M Lo Cascio; M Rizzetto; G Marchesini; A Benedetti
Journal:  Gut       Date:  2007-03-28       Impact factor: 23.059

Review 10.  Adipocytokines and liver disease.

Authors:  Yoshihiro Kamada; Tetsuo Takehara; Norio Hayashi
Journal:  J Gastroenterol       Date:  2008-11-18       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.